Anticancer activity of novel extracts from Cautleya gracilis (Smith) Dandy: Apoptosis in human medullary thyroid carcinoma cells

Anticancer Research

Volumn 28, Issue 5 A, 2008, Pages 2705-2714

  Li, Zengxia ^a,b   Sturm, Sonja ^c   Svejda, Bernhard ^a   Höger, Harald ^d   Schraml, Elisabeth ^a   Ingolic, Elisabeth ^e   Siegl, Veronika ^a   Stuppner, Hermann ^c   Pfragner, Roswitha ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b FUDAN UNIVERSITY   (China)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

Apoptosis; Bioactive agents; Cautleya gracilis; Chemoresistance; Medullary thyroid carcinoma

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CAUTLEYA GRACILIS EXTRACT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CAUTLEYA GRACILIS; CELL ASSAY; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FLOW CYTOMETRY; GINGER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA;

ANIMALS; APOPTOSIS; CARCINOMA, MEDULLARY; CASPASES; CELL LINE, TUMOR; ENZYME ACTIVATION; FEMALE; HUMANS; MICE; MICE, SCID; PLANT EXTRACTS; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZINGIBERACEAE;

EID: 55749094533     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Taggliaferri P and Lupoli G: Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 91: 1797-1808, 2001.
2. Eng C and Mulligan LM: Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumors, and Hirschsprung disease. Hum Mutat 9: 97-109, 1993.
3. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A and Ponder BAJ: Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia syndrome type 2A. Nature (London) 363: 458-460, 1993.
4. Basolo F, Pollina L, Fontani G, Fiore L, Pacini F and Baldanzi A: Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. Br J Cancer 75: 537-541, 1997.
5. Yang KP, Liang YF and Samaan NA: Intrinsic drug resistance in a human medullary thyroid carcinoma cell line: association with overexpression of mdr1 gene and low proliferation fraction. Anticancer Res 11: 1065-1068, 1991.
6. Leong SS, Horoszewicz JS, Shimaoka K, Friedmann M, Kawinski E, Song MJ, Chu T, Baylin S and Mirand EA: A new cell line for study of human medullary thyroid carcinoma. In: Advances in Thyroid Neoplasia. Andreoli M, Monaco H and Robbins J (eds.). Field Educational Italia, Rome, pp. 95-108, 1981.
7. Carlomagno F, Salvatore D, Santoro M, de Franciscis V, Quadro L, Panariello L, Colantuoni V and Fusco A: Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 207: 1022-1028, 1995.
8. Pfragner R, Behmel A, Ingolic E and Wirnsberger GH: Culture of human neuroendocrine tumor cells. In: Culture of Specialized Cells: Culture of Human Tumor Cells. Pfragner R and Freshney RI (eds.). Wiley-Liss & Sons, Hoboken, N J, pp. 373-403, 2004.
9. Pfragner R, Skofitsch G, Hoeger H, Jech M, Rinner B, Siegl V, Niederle B, Gnant M, Friedl J and Stift A: Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination. Anticancer Res 25: 4225-4230, 2005.
10. Pfragner R, Wirnsberger G, Ingolic E and Niederle B: Medullary thyroid carcinomas in cell culture - models for future therapies. Wien Klin Wochenschr 114: 279-283, 2002.
11. Pfragner R, Hoefler H, Behmel A, Ingolic E and Walser V: Establishment and characterization of continuous cell line MTC-SK derived from a human medullary thyroid carcinoma. Cancer Res 50: 4160-4166, 1990.
12. Pfragner R, Wirnsberger G, Behmel A, Wolf G, Passath GA, Ingolic E and Adamiker D: New continuous cell line from human medullary thyroid carcinoma: SINJ. Phenotypic analysis and in vivo carcinogenesis. Int J Oncol 2: 831-836, 1993.
13. Stadler G, Wieser M, Steindl F, Grillari J, Katinger H, Pfragner R and Voglauer R: Development of standardized cell culture conditions for tumor cells with potential clinical application. Cytotherapy 9: 488-498, 2007.
14. Raskin I, Ribnicky DM, Komarnytsky S, Ilic N, Poulev A, Borisjuk N, Brinker A, Moreno DA, Ripoli C, Yakoby N, O'Neal M, Cornwell T, Pastor I and Fridlender B: Plants and human health in the twenty-first century. Trends Biotechnol 20: 522-531, 2002.
15. Olive PL and Durand RE: Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev 13: 121-138, 1994.
16. Steuer AF, Rhim JS, Hentosh PM and Ting RC: Survival of human cells in the aggregate form: potential index of in vitro cell transformation J Natl Cancer Inst 58: 917-21, 1977.
17. St Croix B and Kerbel RS: Cell adhesion and drug resistance in cancer. Curr Opin Cell Biol 9: 549-556, 1997.
18. Rinner B, Siegl V, Pürstner P, Efferth T, Brem B, Greger H and Pfragner R: Activity of novel plant extracts against medullary thyroid carcinoma. Anticancer Res 24: 495-500, 2004.
19. Rinner B, Li ZX, Sturm S, Stuppner H, Siegl V and Pfragner R: Use of cell lines to define new bioassays for the therapy of medullary thyroid carcinoma. Ann Endocrinol 76: P29, Supp 4, 2006.
20. Li ZX, Sturm S, Stuppner H, Schraml E, Aguiriano Moser V, Siegl V and Pfragner R: The dichloromethane fraction of Stemona tuberosa Lour inhibits tumor cell growth and induces apoptosis of human medullary thyroid carcinoma cells. Biologics: Targets Therapy 1(4): 455-463, 2007.